Investigation of unexpected serum CA19-9 elevation in Lewis-negative cancer patients

Annals of Clinical Biochemistry

Volumn 49, Issue 3, 2012, Pages 266-272

  Hamada, Etsuko ^a   Taniguchi, Terumi ^a   Baba, Satoshi ^b   Maekawa, Masato ^a  

^a Department of Laboratory Medicine ^*  (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; DNA;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); DNA SEQUENCE; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEWIS CARCINOMA; MALE; MISSENSE MUTATION; PHENOTYPE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; FEMALE; FUCOSYLTRANSFERASES; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; IMMUNOASSAY; LEWIS BLOOD-GROUP SYSTEM; LUNG NEOPLASMS; MALE; PHENOTYPE; RECTAL NEOPLASMS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84861490452     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1258/acb.2011.011213     Document Type: Article

References (17)

1. Narimatsu H, Iwasaki H, Nakayama F, et al. Lewis and Secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res 1998;58:512-8
2. Nishihara S, Narimatsu H, Iwasaki H, et al. Molecular genetic analysis of the human Lewis histo-blood group system. J Biol Chem 1994;269:29271-8
3. Kudo T, Iwasaki H, Nishihara S, et al. Molecular genetic analysis of the human Lewis histo-blood group system. II. Secretor gene inactivation by a novel single missense mutation A385T in Japanese nonsecretor individuals. J Biol Chem 1996;271:9830-7
4. Mollicone R, Reguigne I, Kelly RJ, et al. Molecular basis for Lewis α (1,3/ 1,4)-fucosyltransferase gene deficiency (FUT3) found in Lewis-negative Indonesian pedigrees. J Biol Chem 1994;269:20987-94
5. Orntoft TF, Vestergaard EM, Holmes E, et al. Influence of Lewis α1-3/4-L-fucosyltransferase (FUT3) gene mutations on enzyme activity, erythrocyte phenotyping, and circulating tumor marker sialyl-Lewis a levels. J Biol Chem 1996;271:32260-8
6. Elmgren A, Borjeson C, Svensson L, Rydberg L, Larson G. DNA sequencing and screening for point mutations in the human Lewis(FUT3) gene enables molecular genotyping of the human Lewis blood group system. Vox Sang 1996;70:97-103
7. Elmgren A, Mollicone R, Costache M, et al. Significance of individual point mutations, T202C and C314T, in the human Lewis (FUT3) gene for expression of Lewis antigens by the human α(1,3/1,4)-fucosyltransferase, Fuc-TIII. J Biol Chem 1997;272:21994-8
8. Nishihara S, Hiraga T, Ikehara Y, et al. Molecular behavior of mutant Lewis enzymes in vivo. Glycobiology 1999;9:373-82
9. Park H-D, Park KU, Song J, Ki C-S, Han KS, Kim JQ. The relationship between Lewis/Secretor genotypes and serum carbohydrate antigen 19-9 levels in a Korean population. Korean J Lab Med 2010;30:51-7
10. Pour PM, Tempero MM, Takasaki H, et al. Expression of blood-group-related antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y, and CA19-9 in pancreatic cancer cells in comparison with the patient's blood group type. Cancer Res 1988;48:5422-6
11. Kawa S, Oguchi H, Kobayashi T, et al. Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype. Br J Cancer 1991;64:899-902.
12. Hirano K, Kawa S, Oguchi H, et al. Loss of Lewis antigen expression on erythrocytes in some cancer patients with high serum CA19-9 levels. J Natl Cancer Inst 1987;79:1261-8.
13. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 1987;47:5501-3
14. Yazawa S, Nishihara S, Iwasaki H, et al. Genetic and enzymatic evidence for Lewis enzyme expression in Lewis-negative cancer patients. Cancer Res 1995;55:1473-8
15. Berger AC, Meszoely IM, Ross EA, Watson JC, Hoffman JP. Undetectable preoperative levels of serum CA19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol 2004;11:644-9
16. Berger AC, Garcia M, Hoffman JP, et al. Postresection CA19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 2008;26:5918-22
17. Kawai S, Suzuki K, Nishio K, et al. Smoking and serum CA19-9 levels according to Lewis and secretor genotypes. Int J Cancer 2008;123: 2880-4